Literature DB >> 21651488

Role of the non-receptor tyrosine kinase fes in cancer.

F Condorelli1, E Stec-Martyna, J Zaborowska, L Felli, I Gnemmi, M Ponassi, C Rosano.   

Abstract

Non receptor protein tyrosine kinases are targets in the treatment of a number of diseases. This review focuses on the role of Fes tyrosine kinase and on the design of inhibitors of this protein. Fes and its homologously related protein Fer are the only two members of a distinct class of non receptor tyrosine kinases and they seem to play a role in cytoskeletal rearrangements and inside-out signaling associated with receptor-ligand, cell-matrix and cell-cell interactions. The knowledge of the three dimensional structure of this protein, in fact, has informed drug design, while at the same time it has helped to shed some light on the molecular mechanism at the basis of kinase activation and functions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21651488     DOI: 10.2174/092986711796150522

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.

Authors:  Masanori Kawakami; Rie Ishikawa; Yosuke Amano; Mitsuhiro Sunohara; Kousuke Watanabe; Nobuya Ohishi; Yutaka Yatomi; Jun Nakajima; Masashi Fukayama; Takahide Nagase; Daiya Takai
Journal:  Cancer Sci       Date:  2013-09-05       Impact factor: 6.716

2.  FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.

Authors:  Masanori Kawakami; Shigeki Morita; Mitsuhiro Sunohara; Yosuke Amano; Rie Ishikawa; Kousuke Watanabe; Emi Hamano; Nobuya Ohishi; Jun Nakajima; Yutaka Yatomi; Takahide Nagase; Masashi Fukayama; Daiya Takai
Journal:  Int J Clin Exp Pathol       Date:  2013-03-15

3.  Integrative analysis of high-throughput RNAi screen data identifies the FER and CRKL tyrosine kinases as new regulators of the mitogenic ERK-dependent pathways in transformed cells.

Authors:  Philippe Nizard; Frédéric Ezan; Dominique Bonnier; Nolwenn Le Meur; Sophie Langouët; Georges Baffet; Yannick Arlot-Bonnemains; Nathalie Théret
Journal:  BMC Genomics       Date:  2014-12-23       Impact factor: 3.969

4.  BRD9 Inhibition, Alone or in Combination with Cytostatic Compounds as a Therapeutic Approach in Rhabdoid Tumors.

Authors:  Katja F Krämer; Natalia Moreno; Michael C Frühwald; Kornelius Kerl
Journal:  Int J Mol Sci       Date:  2017-07-16       Impact factor: 5.923

Review 5.  Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.

Authors:  Kodappully S Siveen; Kirti S Prabhu; Iman W Achkar; Shilpa Kuttikrishnan; Sunitha Shyam; Abdul Q Khan; Maysaloun Merhi; Said Dermime; Shahab Uddin
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

6.  Nuclear factor IX promotes glioblastoma development through transcriptional activation of Ezrin.

Authors:  Zhuohao Liu; Ruixiang Ge; Jiayi Zhou; Xinzhi Yang; Kenneth King-Yip Cheng; Jingli Tao; Dinglan Wu; Jie Mao
Journal:  Oncogenesis       Date:  2020-04-14       Impact factor: 7.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.